WO2023229102A1 - Nouveau peptide de blanchiment et composition cosmétique le contenant - Google Patents
Nouveau peptide de blanchiment et composition cosmétique le contenant Download PDFInfo
- Publication number
- WO2023229102A1 WO2023229102A1 PCT/KR2022/012595 KR2022012595W WO2023229102A1 WO 2023229102 A1 WO2023229102 A1 WO 2023229102A1 KR 2022012595 W KR2022012595 W KR 2022012595W WO 2023229102 A1 WO2023229102 A1 WO 2023229102A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- whitening
- skin
- peptide
- bicelphin
- cosmetic composition
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 88
- 239000002537 cosmetic Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000002087 whitening effect Effects 0.000 title claims description 109
- 230000005764 inhibitory process Effects 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims abstract description 34
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 30
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 30
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 21
- 230000010718 Oxidation Activity Effects 0.000 claims abstract description 18
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims abstract description 10
- 229960004502 levodopa Drugs 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 239000008204 material by function Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 70
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 37
- 238000012360 testing method Methods 0.000 description 36
- 238000011156 evaluation Methods 0.000 description 35
- 239000000047 product Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 230000037303 wrinkles Effects 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000012496 blank sample Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000000069 hyperpigmentation Diseases 0.000 description 4
- 230000003810 hyperpigmentation Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010059516 Skin toxicity Diseases 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 238000013043 cell viability test Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000007689 endotoxicity Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 231100000438 skin toxicity Toxicity 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to a novel whitening peptide and a composition containing the same, and more specifically, to a cosmetic composition that exhibits an excellent skin whitening effect by combining a novel PTD (STeP) with a peptide known to have whitening efficacy.
- STeP novel PTD
- the skin surrounds the entire body and mainly plays the role of protecting the human body from various external irritants.
- interest in healthy and beautiful skin increases in modern society, efforts to improve and maintain it are necessary.
- skin whitening functionality is needed for white and clean skin.
- Skin whitening can be expressed as improving dullness or brightening the skin, and it is known that the difference in a person's skin color depending on race or body part is determined by hemoglobin in the blood or melanin at the border of the epidermis and dermis.
- the biosynthesis of melanin uses tyrosine, a type of amino acid, as a precursor, followed by DOPA, DOPA quinone, and indole-5,6-dihydroquinone, and then indole.
- -It is biosynthesized from melanin, a polymer of 5,6-dihydroquinone.
- Melanin is produced within melanocytes and moves to the boundary between the epidermis and dermis in the form of granules called melanosomes and is deposited there. Melanin is not only the direct cause of dark skin, but also has negative effects on skin beauty, such as promoting the formation of blemishes and freckles.
- PTD Protein transduction domain
- the present invention is a novel whitening peptide that exhibits an excellent skin whitening effect by combining a novel PTD (STeP) with an existing whitening peptide, and is highly purified, non-toxic, safe, and has superior skin whitening effects compared to existing whitening peptides, and a cosmetic product containing the same.
- STeP novel PTD
- the present invention seeks to provide a composition.
- the present invention provides a cosmetic composition for skin whitening, characterized in that it contains a peptide having the amino acid sequence of SEQ ID NO: 1.
- the skin whitening may preferably result from one or more selected from the group consisting of inhibition of tyrosinase activity, inhibition of DOPA oxidation activity, and inhibition of total melanin production in cells.
- novel whitening peptide of the present invention and the cosmetic composition containing it can be obtained in high purity, are non-toxic and safe, and have excellent skin whitening functionality such as inhibition of tyrosinase, inhibition of DOPA oxidation activity, and inhibition of melanin production related to skin whitening. It can demonstrate much better whitening efficacy than existing whitening peptides. In addition, when actually applied to cosmetics, it can demonstrate excellent skin functionality together with other types of functional substances.
- Figure 1 shows the results of an in-house analysis of the purity of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 2 shows the results of a consignment analysis of the purity of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 3 shows the results of an endotoxin quantitative test for the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 4 shows the cell viability test results (self-evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 5 shows the results of a tyrosinase activity inhibition test (self-evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 6 shows the results of an L-DOPA oxidation activity inhibition test (self-evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 7 shows the results of a test (self-evaluation) measuring the total amount of melanin produced in cells of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 8 shows the cell viability test results (consignment evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 9 shows the results of a tyrosinase activity inhibition test (commissioned evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 10 shows the results of an L-DOPA oxidation activity inhibition test (commissioned evaluation) of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 11 shows the results of a test (consignment evaluation) measuring the total amount of melanin produced in cells of the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 12 shows the results of a comparative test for tyrosinase activity inhibition between the whitening peptide Bicelphin-oligopeptide68 of the present invention and the existing whitening peptide oligopeptide68.
- Figure 13 shows the results of a comparative test on the inhibition of L-DOPA oxidation activity between the whitening peptide Bicelphin-oligopeptide68 of the present invention and the existing whitening peptide oligopeptide68.
- Figure 14 shows the results of a comparative test measuring the total amount of melanin produced in cells between the whitening peptide Bicelphin-oligopeptide68 of the present invention and the existing whitening peptide oligopeptide68.
- Figure 15 is a result graph showing changes in skin wrinkle parameters of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 16 is an optical photograph and a 3D photograph showing changes in skin wrinkles in a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 17 is a result graph showing changes in skin brightness and color parameters of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 18 is a graph showing the change in skin melanin index of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 19 is a result graph showing changes in skin transparency parameters of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 20 is a graph showing the change in skin gloss of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 21 is a photo showing the change in skin gloss of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 22 is a result graph showing changes in skin tone and tone uniformity of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 23 is a photograph showing the change in skin tone uniformity of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 24 is a graph showing the change in skin density of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 25 is a photograph showing the change in skin density of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 26 shows the results of a questionnaire evaluation on the efficacy of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- Figure 27 shows the results of a questionnaire evaluation regarding the usability of a cosmetic composition containing the whitening peptide Bicelphin-oligopeptide68 of the present invention.
- the present invention provides a cosmetic composition for skin whitening, characterized in that it contains a peptide having the amino acid sequence of SEQ ID NO: 1.
- the peptide having the amino acid sequence of SEQ ID NO: 1 is listed in the International Cosmetic Ingredient Dictionary (ICID) as "Bicelphin-BWP1", and its INCI (International Nomenclature Cosmetic Ingredient) name is "Oligopeptide-68 Oligopeptide-133". It was registered as.
- an existing whitening peptide by combining Bicelphin, a novel PTD (STeP), with oligopeptide68, known as an existing whitening peptide, it inhibits tyrosinase better than existing whitening peptides. , it was able to demonstrate excellent skin whitening efficacy through inhibition of DOPA oxidation activity and inhibition of total melanin production within cells.
- the skin whitening may result from one or more selected from the group consisting of inhibition of tyrosinase activity, inhibition of DOPA oxidation activity, and inhibition of total melanin production within cells.
- the peptide having the amino acid sequence of SEQ ID NO: 1 may preferably be included in an amount of 0.0001 to 0.001% by weight, more preferably 0.0005% by weight, based on the total weight of the cosmetic composition. may be included.
- the cosmetic composition of the present invention is not limited to a specific form (formulation) and includes all formulations, such as lotion, gel, water-soluble liquid, cream, essence, oil-in-water (O/W) type, and water-in-oil type.
- W/O type emulsion basic cosmetic formulation consisting of ointment, oil-in-water and water-in-oil makeup base, foundation, skin cover, lipstick, lip gloss, face powder, two-way cake, eye shadow, cheek color, and eyebrow pencils It is better to use any one selected from color cosmetic formulations consisting of.
- the cosmetic composition of the present invention may contain auxiliaries common in the cosmetic field such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic activators, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, odorants and dyes. It may be possible.
- the novel Bicelphin-oligopeptide68 peptide of the present invention can be obtained in high purity and has no possibility of skin toxicity.
- the novel Bicelphin-oligopeptide68 peptide of the present invention can be used as a functional material that exhibits various effects related to skin whitening when applied and manufactured as an actual cosmetic composition.
- a new whitening peptide was developed by combining a new PTD (STeP) with an existing whitening peptide.
- the synthesis and purification method of skin-permeable whitening peptide was solid phase peptide synthesis (SPPS, Solid Phase Peptide Synthesis).
- SPPS Solid Phase Peptide Synthesis
- Peptides by chemical synthesis are composed of C-Terminal to N-Terminal, and chemical synthesis includes the classic liquid phase method and solid phase method.
- the peptide of the present invention was synthesized using a solid phase method.
- the peptide developed through this was PTD-oligopeptide68 (hereinafter referred to as Bicelphin-oligopeptide68), and detailed information was shown in Table 1 below.
- Liquid chromatography was used to analyze purity.
- Liquid chromatography is characterized by separating the components of a mixture using a mobile phase (liquid) and a stationary phase (column). The purpose of the experiment is mainly to measure the size of the reaction of chemical substances over time using a detector. It is a method of quantifying substances.
- the experiment was conducted using water and acetonitrile (ACN) as polar solvents and C18, a reversed-phase hydrophilic column, as the solvent for the sample and mobile phase whose purity is to be determined.
- the solvent was prepared by adding 0.1% of trifluoroacetic acid to water and acetonitrile (ACN) for acid stability and used after removing air bubbles. Samples were prepared by filtering and injecting each into vials. To stabilize the device before the separation process, wash the pump 2-3 times with 100% acetonitrile, install a C18 column, and flow acetonitrile until the pressure and temperature are stabilized. Once the pressure was stabilized, the program was set and the purity of the protein was determined by measuring the size of the peak over time under the UV detection wavelength (214 nm, 280 nm).
- the purity of the whitening peptide by HPLC was analyzed through in-house and consignment analysis, and as shown in Table 2 and Figures 1 and 2 (Bicelphin-BWP1 was analyzed, but the test sample name is written as BWP-1 for convenience), the result was 99.82. It has a high purity of 99.16%, which is considered to be equal or higher than the purity of other protein and peptide raw materials currently distributed in the cosmetic raw material market.
- B16F10 cells were inoculated into a 24 -well plate at a concentration of 1.5 After incubation, 10ul Ez-cytox was added to each well, incubated for 1 hour, and absorbance was measured at 450 nm.
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) was confirmed to have no cytotoxicity compared to the solvent control group at a concentration of 50 uM or less.
- Tyrosinase is an enzyme involved in the most important initial rate-determining step in the melanin biosynthesis pathway in the human body, and inhibition of the activity of this enzyme results in inhibition of melanin production.
- This test is a method to evaluate the effect of the test sample on inhibiting tyrosinase activity by reacting the test sample, purified tyrosinase, and the substrate tyrosine in vitro.
- the sample was dissolved in ethanol or an appropriate solvent, diluted to set a concentration range in which inhibition of tyrosinase activity can be confirmed, and treated to achieve at least 5 concentrations.
- 220 ⁇ L of 0.1 M phosphate buffer (pH 6.5), 20 ⁇ L of sample solution, and 20 ⁇ L of mushroom tyrosinase solution (1,500 U/mL to 2,000 U/mL) (or human tyrosinase) were added to the test tube in that order.
- 40 ⁇ L of 1.5-2 mM tyrosine solution was added and reacted at 37°C for 10-15 minutes, and then the absorbance was measured at 490 nm.
- the blank sample solution was corrected using the solvent in which the sample was dissolved instead of the sample solution, and the results were compared using arbutin as a positive control.
- the inhibition rate of tyrosinase activity was confirmed using Equation 1 below.
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) significantly reduced tyrosinase activity to 8.57-29.33% compared to the solvent control group at a concentration of 6.25-50 uM.
- L-DOPA L-3,4-dihydroxyphenylalanine
- the sample was dissolved in ethanol or an appropriate solvent, diluted to set a concentration range that can confirm the inhibition of tyrosinase activity for the DOPA oxidation reaction, and treated to achieve at least 5 concentrations.
- 170 ⁇ L of 0.1 M phosphate buffer (pH 7.0), 10 ⁇ L of sample solution, and 10 ⁇ L of mushroom tyrosinase solution (1,500 U/mL ⁇ 2,000 U/mL) (or human tyrosinase) were added to the test tube in that order.
- 10 ⁇ L of 8 mM L-DOPA solution was added, reacted at 37°C for 30 minutes, and absorbance was measured at 475 nm.
- the blank sample solution was corrected using a solvent in which the sample was dissolved instead of the sample solution, and arbutin was used as a positive control and the results were compared and measured.
- the inhibition rate of L-DOPA oxidation reaction was confirmed using Equation 2 below.
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) significantly reduced the L-DOPA oxidation activity to 5.88-21.46% compared to the solvent control group at a concentration of 6.25-50 uM.
- cells were cultured, the amount of melanin inside the cells or the total amount of melanin inside and outside the cells was quantified and compared with a blank sample solution.
- B16F10 melanoma cells Mouse melanoma cells (B16F10 melanoma cells) were selected and used based on efficacy test data from the Ministry of Food and Drug Safety's "Guidelines for the evaluation of effectiveness of functional cosmetics that help whiten the skin.” B16F10 cells were inoculated on the bottom of a culture dish, then DMEM mixed medium containing 1% Antibiotic-Antimycotic and 10% FBS was added and cultured in an incubator at 37°C and 5% CO 2 .
- B16F10 cells were inoculated into a 6-well plate at a concentration of 1 ⁇ 10 5 cells/well and cultured for 24 hours under cell culture conditions. The medium was removed, the cells were washed with PBS, and then new medium without phenol red containing test substances diluted at each concentration and 100 nM ⁇ -MHS was added and cultured for 72 hours, and then the medium was removed. . Cells were washed with PBS, lysed at 60°C by adding 1M NaOH to each well, centrifuged, and the absorbance of the supernatant was measured at 490 nm.
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) significantly reduced the total melanin production by 29.72-50.18% compared to the solvent control group at a concentration of 6.25-50 uM.
- B16F10 melanoma cells were inoculated into a 24 -well plate at a concentration of 1.5 After 72 hours of incubation, changes in cell shape due to test substance treatment at each concentration were observed under a microscope. MTT solution was added to each well to a final treatment concentration of 0.05% and cultured for 4 hours. After removing the culture medium, 1,000 ⁇ L of DMSO was added and shaken for more than 1 hour, and the absorbance was measured at 540 nm (Microplatereader; Epoch2, BioTek, USA).
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention had no cytotoxicity and no cell shape or change compared to the solvent control group at a concentration of 50 uM or less (Mean ⁇ SD, p ⁇ 0.05).
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention significantly reduced tyrosinase activity to 13.19-25.86% compared to the solvent control group at a concentration of 6.25-50 uM (Mean ⁇ SD, p ⁇ 0.05).
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention significantly reduced L-DOPA oxidation activity by 7.61-16.23% compared to the solvent control group at a concentration of 6.25-50 uM (Mean ⁇ SD, p ⁇ 0.05).
- B16F10 melanoma cells were inoculated into a 6-well plate at a concentration of 1 ⁇ 10 5 cells/well and cultured for 24 hours under cell culture conditions. The medium in each well was removed, the cells were washed with PBS, and then new cell culture medium without Phenol red containing diluted test substances of each concentration and 100 nM ⁇ -MSH was added and cultured for 72 hours. The cultured cells were used to measure the amount of intracellular melanin, and the cell culture medium was used to measure the amount of extracellular melanin. The total amount of melanin produced by the cells was calculated by adding the amount of melanin inside and outside the cells.
- the cultured cells were washed with PBS, dissolved at 60°C by adding 1M NaOH to each well, and the absorbance of the lysed solution was measured at 400 nm.
- the cells were The culture medium was transferred to a 1.5 ml tube, centrifuged, and the supernatant was transferred to a 96-well plate and absorbance was measured at 400 nm.
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention significantly reduced the total melanin production of cells by 25.12-48.24% compared to the control group treated alone with ⁇ -MSH at a concentration of 6.25-50 uM ( Mean ⁇ SD, p ⁇ 0.05).
- Bicelphin-oligopeptide68 a novel whitening peptide developed in the present invention by combining a novel PTD (STeP) with an existing whitening peptide, inhibits tyrosinase activity, L -It was found to be a substance with a whitening effect due to its excellent efficacy in inhibiting DOPA oxidation activity and total melanin production in cells.
- STeP novel PTD
- L -It was found to be a substance with a whitening effect due to its excellent efficacy in inhibiting DOPA oxidation activity and total melanin production in cells.
- Bicelphin-oligopeptide68 Boicelphin-BWP1
- a novel whitening peptide developed in Example 1 combining a novel PTD (STeP) with an existing whitening peptide
- STeP novel PTD
- BWP1 existing whitening peptide oligopepetide68
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention shows a concentration-dependent decreasing trend compared to the solvent control group at a concentration of 6.25 to 50 uM, but in particular, the existing It was found to have a greater effect on whitening by showing superior tyrosinase inhibition efficacy (8.57-29.33%) than the whitening peptide BWP1 (0-15.76%).
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention shows a concentration-dependent decreasing trend compared to the solvent control group at a concentration of 6.25 to 50 uM, but in particular, the existing It was found to have a greater effect on whitening as it showed superior DOPA oxidation activity inhibition efficacy (5.88-21.46%) than the whitening peptide BWP1 (2.62-19.82%).
- Bicelphin-oligopeptide68 (Bicelphin-BWP1) of the present invention shows a concentration-dependent decreasing trend compared to the solvent control group, but in particular, , it was found to have a greater effect on whitening by showing superior melanin production inhibition efficacy (29.72-50.18%) than the existing whitening peptide, BWP1 (16.28-38.42%).
- the new whitening peptide developed in the present invention by combining the existing whitening peptide with the new PTD (STeP) is a material that can be applied as a material with a much more effective whitening effect than the existing whitening peptide.
- an ampoule-type cosmetic product was prepared as an example of a cosmetic composition containing the novel whitening peptide developed in Example 1, and the detailed composition was shown in Table 4.
- Bicelphin-oligopeptide68 0.0005 Peptide A (Has the amino acid sequence of SEQ ID NO: 2) 0.0005 Peptide B (Binding of a peptide with the amino acid sequence of SEQ ID NO. 3 and tranexamic acid) 0.0005 Peptide C (Has the amino acid sequence of SEQ ID NO: 4) 0.0005 Peptide D (Has the amino acid sequence of SEQ ID NO: 5) 0.0005 glycerin 7.65 Butylene glycol 9.95 1,2-hexanediol 0.097 Propanediol 1.2 Sodium Hyaluronate 0.04 Purified water to 100
- the skin irritation safety evaluation was conducted by DermaPro Co., Ltd., and the method and results were as follows.
- Test subjects and number 30 women (34.50 ⁇ 7.22 years old) who met the selection and exclusion criteria.
- PCPC Personal Care Products Council
- Mean Example 2 0 - - - - - - - - - 0.0
- Example 2 of the present invention was stable as a material in the hypoallergenic category in terms of primary irritation of human skin.
- Test subjects and number 21 female subjects aged 38 to 60 years (average 49.76 ⁇ 5.36 years).
- novel whitening peptide developed in the present invention can be used as a functional material that exhibits various effects related to skin whitening in actual cosmetic compositions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention se rapporte à une composition cosmétique qui présente un effet considérable de blanchiment de la peau par liaison d'un nouveau PTD (STeP) à un peptide présentant un effet connu de blanchiment de la peau. La composition cosmétique peut être obtenue à une pureté élevée, n'est pas toxique et est donc sûre, et présente une fonctionnalité considérable de blanchiment de la peau, telle que l'inhibition de la tyrosinase, l'inhibition de l'activité d'oxydation de la DOPA, et l'inhibition de la production de mélanine, qui sont associées au blanchiment de la peau, et peut ainsi présenter un effet de blanchiment de la peau bien supérieur à celui des peptides de blanchiment de la peau classiques. De plus, la composition cosmétique peut présenter une fonctionnalité cutanée considérable conjointement avec d'autres types de matériaux fonctionnels lorsqu'elle est réellement appliquée à des produits cosmétiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2022-0064697 | 2022-05-26 | ||
KR1020220064697A KR102717793B1 (ko) | 2022-05-26 | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023229102A1 true WO2023229102A1 (fr) | 2023-11-30 |
Family
ID=88919318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/012595 WO2023229102A1 (fr) | 2022-05-26 | 2022-08-23 | Nouveau peptide de blanchiment et composition cosmétique le contenant |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023229102A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117801070A (zh) * | 2024-03-01 | 2024-04-02 | 中国农业大学 | 一种美白祛斑消水肿青稞酒糟肽及其制备方法和应用 |
CN118005729A (zh) * | 2024-02-27 | 2024-05-10 | 中国农业大学 | 一种具有酪氨酸酶抑制活性的多肽及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1686081A (zh) * | 2005-04-12 | 2005-10-26 | 福州大学 | Ptd-sod融合蛋白及其衍生物在化妆品中的应用 |
KR101095841B1 (ko) * | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
WO2016146778A1 (fr) * | 2015-03-17 | 2016-09-22 | Inderm | Procédés de fourniture de soins cutanés par photothérapie |
KR20170114997A (ko) * | 2016-04-06 | 2017-10-16 | 이화여자대학교 산학협력단 | 세포막 투과성을 갖는 펩타이드 |
-
2022
- 2022-08-23 WO PCT/KR2022/012595 patent/WO2023229102A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1686081A (zh) * | 2005-04-12 | 2005-10-26 | 福州大学 | Ptd-sod融合蛋白及其衍生物在化妆品中的应用 |
KR101095841B1 (ko) * | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
WO2016146778A1 (fr) * | 2015-03-17 | 2016-09-22 | Inderm | Procédés de fourniture de soins cutanés par photothérapie |
KR20170114997A (ko) * | 2016-04-06 | 2017-10-16 | 이화여자대학교 산학협력단 | 세포막 투과성을 갖는 펩타이드 |
Non-Patent Citations (1)
Title |
---|
PRATCHYAPURIT WALAI-ORN: "Combined use of two formulations containing diacetyl boldine, TGF-B1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than", JOURNAL OF COSMETIC DERMATOLOGY, BLACKWELL SCIENCE, OXFORD, GB, vol. 15, no. 2, 1 June 2016 (2016-06-01), GB , pages 131 - 144, XP055777014, ISSN: 1473-2130, DOI: 10.1111/jocd.12201 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118005729A (zh) * | 2024-02-27 | 2024-05-10 | 中国农业大学 | 一种具有酪氨酸酶抑制活性的多肽及其应用 |
CN117801070A (zh) * | 2024-03-01 | 2024-04-02 | 中国农业大学 | 一种美白祛斑消水肿青稞酒糟肽及其制备方法和应用 |
CN117801070B (zh) * | 2024-03-01 | 2024-06-07 | 中国农业大学 | 一种美白祛斑消水肿青稞酒糟肽及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20230164937A (ko) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023229102A1 (fr) | Nouveau peptide de blanchiment et composition cosmétique le contenant | |
WO2022145663A1 (fr) | Composition cosmétique comprenant une masse de bactéries lactiques lactobacillus plantarum mortes ou une culture de bactéries lactiques destinée à prévenir ou à atténuer le vieillissement de la peau | |
JP5596922B2 (ja) | 顔の皺を減らすおよび/または取り除くためのエンケファリン誘導ペプチドを含む化粧品または皮膚用薬剤組成物 | |
KR20000068645A (ko) | 피부 색소 침착을 치료하기 위한 방법 | |
WO2020004745A1 (fr) | Micro-aiguille revêtue d'un médicament et son procédé de fabrication | |
US5126327A (en) | Melanocyte-stimulating hormone inhibitor and external preparation containing the same | |
WO2019004543A1 (fr) | Composition cosmétique de peptide régulateur de neurotransmetteur à perméabilité transdermique améliorée | |
WO2018004281A2 (fr) | Acide tranexamique-peptide ayant une activité de blanchiment de la peau et ses utilisations | |
WO2017159922A1 (fr) | Conjugué de finastéride avec un peptide | |
WO2018034453A1 (fr) | Conjugué de minoxidil et d'un peptide | |
WO2024048965A1 (fr) | Peptide complexe pour blanchiment et composition cosmétique le contenant | |
WO2017116138A1 (fr) | Peptide inhibiteur de la mélanine et composition le contenant | |
WO2017119756A1 (fr) | Nouveau peptide fonctionnel anti-inflammatoire, blanchissant la peau, anti-âge et atténuant les rides, et composition contenant le peptide | |
WO2023055010A1 (fr) | Peptide ayant une activité anti-âge et son utilisation | |
WO2023054817A1 (fr) | Peptide ayant une activité anti-âge et son utilisation | |
KR20210145476A (ko) | 신규 펩타이드 유도체 및 이를 유효성분으로 포함하는 피부 타이트닝 또는 윤곽 개선용 조성물 | |
WO2023055007A1 (fr) | Peptide possédant une activité anti-vieillissement, et son utilisation | |
WO2018208124A2 (fr) | Conjugué d'isotrétinoïne et d'un peptide | |
WO2022255809A1 (fr) | Composition cosmétique imitant le placenta | |
WO2021251791A1 (fr) | Peptide présentant une activité de type toxine botulique et utilisation correspondante | |
WO2021241780A1 (fr) | Composition destinée à inhiber le grisonnement des cheveux, et son utilisation | |
KR102717793B1 (ko) | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 | |
WO2020222315A1 (fr) | Composition pour améliorer ou traiter des rides cutanées ayant une excellente perméabilité cutanée ou cellulaire | |
WO2024177448A1 (fr) | Nouveau peptide ayant une activité d'amélioration de l'état de la peau et composition cosmétique le contenant | |
WO2018151352A1 (fr) | Conjugué d'acide salicylique et de peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22943909 Country of ref document: EP Kind code of ref document: A1 |